1. Home
  2. Labeler Index
  3. Sanja Pharmaceuticals Company
  4. 57277-002
  5. Product Images: Oxaliplatin

Product Images Oxaliplatin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Oxaliplatin NDC 57277-002 by Sanja Pharmaceuticals Company, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

100 mg carton - 100mg 20ml carton rev

100 mg carton - 100mg 20ml carton rev

This is a description of a medical product called Oxaliplatin Injection. It is manufactured by Alidec Pharmaceuticals Limited and contains the active ingredient Oxaliplatin in a sterile, aqueous solution. Each vial contains 100 mg/20 mL of Oxaliplatin Injection, which should be stored at 25°C and protected from light. The product should be used only for intravenous use and should not be mixed with or added to sodium chloride/chloride-containing solutions. Dosage and administration instructions are available in the package insert.*

bottle 50 mg - 50mg 5ml bottle rev

bottle 50 mg - 50mg 5ml bottle rev

The text is not readable.*

Figure 2 - DFS Kaplan-Meier - dfs fig 02

Figure 2 - DFS Kaplan-Meier - dfs fig 02

Figure 3 - DFS Kaplan-Meie - dfs fig03

Figure 3 - DFS Kaplan-Meie - dfs fig03

This appears to be a graph or chart showing the DFS (disease-free survival) probability in months for different treatment arms in a clinical trial. The X-axis shows the months and the Y-axis shows the DFS percentage. The treatment arms appear to be FOLFOX4 and LVoFU2 for Dukes C stage, and there is a Hasard Ratio percentage of 6% for G070. The may have missed some important details, but overall it seems to be a representation of clinical trial data.*

figure 01 - fig 01

figure 01 - fig 01

This is a chemotherapy regimen that includes two days of treatment. On day 1 and day 2, the patient will receive a bolus injection of 400 mg/m of 5-FU over 2-4 minutes. On day 1 and day 2, they will also receive a Leucovorin infusion - 200 mg/m on both days. On day 2, the Leucovorin infusion will be accompanied by a 600 mg/m infusion of 5-FU. Additionally, on both days, the patient will receive an 85mg/m injection of Oxaliplatin at various times throughout the day. The time intervals for Oxaliplatin injection are not completely clear.*

Figure 4 – Kaplan-Meier - fig 04

Figure 4 – Kaplan-Meier - fig 04

structure - structure 01

structure - structure 01

100 mg vial - vial 100mg vial rev

100 mg vial - vial 100mg vial rev

vial 50 mg - vial 50mg rev

vial 50 mg - vial 50mg rev

This is the label information of Oxaliplatin Injection USP, manufactured in India by NDC Pharmaceuticals Ltd. The injection comes in a 10 mL vial containing 50mg/10mL Oxaliplatin and water for injection. The solution is sterilized and preservative-free. It is recommended to store at 15-30°C. The package insert contains dosage and administration data, required dilution, and other instructions. The injection is meant for intravenous use only.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.